Immune Design
Latest round
- Series C
Last raised
- Oct 2013
Total raised
- $90M
Investors
- 7
About Immune Design
Founded in 2008 and based in Washington, US, Immune Design Corp. is a biotechnology company that focuses on developing vaccines and immunotherapies for infectious diseases and cancer. The company offers G100, an intratumoral immune activation designed to leverage endogenous antigens and create a systemic anti-tumor immune response from a local injection, and NY-ESO-1, a tumor antigen for the treatment of synovial and MRCL sarcoma.
Who invested in Immune Design
7 investors across 4 rounds
See all investors in Immune Design
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immune Design
Who invested in Immune Design?
Immune Design has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immune Design raised?
Immune Design has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Immune Design last raise money?
Immune Design's most recent round on record is a Series C, in Oct 2013.
What does Immune Design do?
Founded in 2008 and based in Washington, US, Immune Design Corp.
Where is Immune Design headquartered?
Immune Design is headquartered in Seattle, US.
Which VCs invest in companies like Immune Design?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Immune Design's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Immune Design? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.